DORMANT studio
localhost:3000

Opportunity radar

4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05

Showing50 of 77,862
Free-text
CPC starts with (comma sep)
Min fwd citations
Clear
Patent #TitleAssetsIssuedExpiresFwd citesScore
12618048Dual CAR-T cells🖼🧊📄§2026-05-052041-07-30031
12617774Substituted indole compounds and methods of use thereof🖼🧊📄§2026-05-052045-05-30031
12617853Low pH pharmaceutical composition comprising T cell engaging antibody constructs🖼🧊📄§2026-05-052038-02-02031
12617854Humanized or chimeric CD3 antibodies🖼🧊📄§2026-05-052042-05-09031
12616755Antifungal quercetin conjugates, methods of preparation and uses thereof🖼🧊📄§2026-05-052045-10-08031
12616652Lenses for treating ocular diseases and preparation method thereof🖼🧊📄§2026-05-052042-12-29031
12616745Influenza virus backbone🖼🧊📄§2026-05-052040-06-05031
12616733XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions🖼🧊📄§2026-05-052041-02-10031
12616714Enhanced oligonucleotides for modulating FUBP1 expression🖼🧊📄§2026-05-052041-06-25031
12616749Methods for treatment of psoriasis with an anti-oxLDL antibody🖼🧊📄§2026-05-052044-06-21031
12616685Concomitant administration of glucocorticoid receptor modulator relacorilant and CYP2C9 substrates🖼🧊📄§2026-05-052041-05-26031
12616782Use of mitochondria to treat and/or prevent tendon injury or its related disease🖼🧊📄§2026-05-052041-03-19031
12616721Stratified squamous epithelial cell normal differentiation and maturation promoting agent, epithelial disease therapeutic agent, and stratified squamous epithelial cell normal differentiation and maturation promoting method🖼🧊📄§2026-05-052039-01-11031
12616751Photosensitizing antibody-fluorophore conjugates🖼🧊📄§2026-05-052042-06-15031
12616696Crystalline forms of (p)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2′-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5′,6-dimethyl-2h-[1,4′-bipyridin]-2-one🖼🧊📄§2026-05-052041-03-26031
12616663Plant-derived exosome-like nanoparticles inhibit bacterial pathogenicity🖼🧊📄§2026-05-052040-03-02031
12617838Auto/allo-immune defense receptors for the selective targeting of activated pathogenic T cells and NK cells🖼🧊📄§2026-05-052039-04-25031
12617848Methods of treating ocular pathologies using bifunctional molecules that target growth factors🖼🧊📄§2026-05-052041-11-08031
12617834Composition of NY-ESO-1-specific t cell receptors restricted on multiple major histocompatibility complex molecules🖼🧊📄§2026-05-052039-09-04031
12617842Antiviral immunotherapy by membrane receptor ligation🖼🧊📄§2026-05-052041-12-02031
12617818Compositions and methods for modulating myosin subfragment-2 coiled coil stability and methods for using them🖼🧊📄§2026-05-052041-03-25031
12618067Targeted delivery of an inhibitor of miR-21 to macrophages for the treatment of pulmonary fibrosis🖼🧊📄§2026-05-052041-04-09031
12618060Nucleic acid molecules🖼🧊📄§2026-05-052041-03-15031
12618832Identification of cognate pairs of ligands and receptors🖼🧊📄§2026-05-052039-12-19031
12617727Method for producing zirconia sintered body🖼🧊📄§2026-05-052040-12-18031
12618840Antibody for detecting acetylation of COX2 protein, and uses thereof🖼🧊📄§2026-05-052040-09-18031
12616758Freeze-dried composition for preparing calibrated gas-filled microvesicles🖼🧊📄§2026-05-052040-06-24031
12617863Humanized anti-glycoprotein Ib alpha (GPIbalpha) antibodies🖼🧊📄§2026-05-052040-12-10031
12616680Combined use of biotin and thiamine in the treatment of huntington's disease🖼🧊📄§2026-05-052040-09-23031
12616688Cell glycocalyx protection effect of anisodamine🖼🧊📄§2026-05-052041-09-01031
12616699Ophthalmic formulations of methotrexate🖼🧊📄§2026-05-052040-09-11031
12616695Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of rare chronic inflammatory pulmonary diseases🖼🧊📄§2026-05-052041-01-29031
12616717Regenerative CO2 treatment apparatus and method🖼🧊📄§2026-05-052040-07-09031
12616730Topical composition comprising an extract of combined herbs comprising longanae arillus for the treatment or alleviation of skin ulcer and the use thereof🖼🧊📄§2026-05-052041-03-10031
12616602Bacteria formulation and products including same🖼🧊📄§2026-05-052041-08-04031
12616750Combination therapy utilizing DNA alkylating agents and ATR inhibitors🖼🧊📄§2026-05-052039-10-14031
12616702Use of reboxetine to treat narcolepsy🖼🧊📄§2026-05-052044-08-29031
12616673Compounds for use in the treatment of leukemia🖼🧊📄§2026-05-052041-01-28031
12616713Methods for enhancing vascular density🖼🧊📄§2026-05-052043-01-20031
12616703Methods of contraception using nomegestrol acetate and estradiol🖼🧊📄§2026-05-052041-10-12031
12616674Anti-fibrotic NEU3 inhibitor compounds and methods of use🖼🧊📄§2026-05-052040-02-10031
12616716Wound healing dressings and formulations and methods of use thereof🖼🧊📄§2026-05-052044-12-11031
12616667Compositions and methods for improving neurological diseases and disorders🖼🧊📄§2026-05-052042-11-14031
12617766Crystal form of thiophene derivative and preparation method therefor🖼🧊📄§2026-05-052042-04-21031
12617782Pyridazinones as PARP7 inhibitors🖼🧊📄§2026-05-052043-05-12031
12617765Cannabinoid derivatives🖼🧊📄§2026-05-052040-11-27031
12617830Analogues of PYY🖼🧊📄§2026-05-052043-11-30031
12618070Increasing Atoh1 life to drive sensorineural hair cell differentiation🖼🧊📄§2026-05-052042-03-04031
12617783Heterocyclic GLP-1R agonists🖼🧊📄§2026-05-052045-03-28031
12618059Anc80 encoding sphingolipid-metabolizing proteins🖼🧊📄§2026-05-052039-03-07031